BioCentury
ARTICLE | Clinical News

LOR-253: Phase I data

July 29, 2013 7:00 AM UTC

An open-label, dose-escalation, U.S. Phase I trial in 27 patients with advanced or metastatic solid tumors who previously failed a median of 4 prior chemotherapies showed that 20-229 mg/m 2 doses of L...